ClinicalTrials.gg
CompletedNCT00735904Updated Jan 3, 2013Results posted

Trial Of AG-013736, Cisplatin, And Gemcitabine For Patients With Squamous Non-Small Cell Lung Cancer

A Phase 2 interventional study of AG-013736 and gemcitabine in Carcinoma, Non-Small-Cell Lung (NSCLC), sponsored by Pfizer. Completed at 10 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-01-03.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
38
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Carcinoma by Pfizer — 6 open to participants now, 6 under way, 2 of them phase 3. Carcinoma · Pfizer.

Enrollment
20th of 24
38 · median 98
Started
2008
with 5 others
Phase 2
8 of 27
1 open now
Registered
13th of 27
by date

Among the 27 studies in Carcinoma by Pfizer, this one is the 20th largest by enrollment of the 24 interventional ones that give a count, is one of 6 that started in 2008, is one of 8 in phase 2, and was the 13th registered.

Carcinoma

736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.

Browse Carcinoma studies →

Open to participants now

6 of the 27 studies in Carcinoma by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 115 Carcinoma studies recruiting now, 92 (80%) set no upper age limit and 14 (12%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Carcinoma by Pfizer, or all of them as a file.
02

Study summary

This study will evaluate whether AG-013736 when combined with cisplatin and gemcitabine shows activity and is safe in patients with squamous type of non-small cell lung cancer

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung (NSCLC)

Keywords

  • AG-013736
  • axitinib
  • cisplatin
  • gemcitabine
  • NSCLC
  • squamous cell
  • lung cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • - or cytologically-confirmed diagnosis of squamous NSCLC Stage IIIB with malignant effusion (fluid cytology demonstrating malignant cells required), Stage IV, or recurrent disease after definitive local therapy
  • Candidate for primary treatment with cisplatin and gemcitabine
  • Presence of by
  • Adequate organ function as defined by the following criteria: performance status of 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Prior systemic treatment for Stage IIIB (with malignant effusion) or Stage IV NSCLC.
  • One or more lung lesions with cavitation, or any lesion invading or abutting a major blood vessel as assessed by CT or MRI.
  • History of hemoptysis > ½ tsp (2.5 ml) of blood per day for a day or more within 1 week of study treatment, or Grade 3 or 4 hemoptysis within 4 weeks of study treatment
  • Grade 3 hemorrhage from any cause within 4 weeks of study treatment
  • Preexisting uncontrolled hypertension as documented by 2 baseline blood pressure readings taken at least 1 hour apart.
  • Untreated .
  • Need for therapeutic anticoagulation, regular use of aspirin (> 325 mg/day), NSAID or other medications known to inhibit function.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    AG-013736/Cisplatin/Gemcitabine

    Drug: AG-013736 · Drug: gemcitabine · Drug: cisplatin

Interventions

  • AG-013736 5 mg tablets orally, twice daily, until disease progression

    Also known as: axitinib

  • 200-mg or 1 g lyophilized powder, to be administered as 1250 mg/m\^2 IV infusion on Day 1 and Day 8 of 21-day cycle. For a maximum of 6 cycles

  • 1mg/ml solution or as lyophilized powder, to be administered as 80 mg/m\^2 IV infusion on Day 1 of 21-day cycle. For a maximum of 6 cycles

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Objective Response (OR)

    Percentage of participants with objective response based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed response are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are those with disappearance of all target lesions. PR are those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions.

    Time frame: Baseline until disease progression or discontinuation from the study due to any cause, assessed every 6 weeks during chemotherapy phase and every 8 weeks during single agent phase up to final study visit (Week 78)

Secondary outcomes

  1. Overall Survival (OS)

    Time in months from the start of study treatment to date of death due to any cause. OS was calculated as (the death date minus the date of first dose of study medication plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).

    Time frame: Baseline until death or assessed every 2 months (up to 28 days after the last dose)

  2. Progression Free Survival (PFS)

    Time in months from start of study treatment to the first documentation of objective tumor progression or to death due to any cause. PFS calculated as (Months) = (first event date minus first dose date plus 1) divided by 30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").

    Time frame: Baseline, assessed every 2 months (up to 28 days after the last dose)

  3. Duration of Response (DR)

    Time in months from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response.

    Time frame: Baseline until disease progression or discontinuation from the study due to any cause, assessed every 6 weeks during chemotherapy phase and every 8 weeks during single agent phase up to final study visit (Week 78)

07

Results

Posted Jan 3, 2013

Participant flow

Participant flow — Overall Study
MilestoneAxitinib + Cisplatin + Gemcitabine
Started38
Completed0
Not completed38
Withdrew: Adverse event3
Withdrew: Death20
Withdrew: Protocol violation1
Withdrew: Withdrawal by subject1
Withdrew: Study terminated by sponsor5
Withdrew: Other8

Outcome measures

PrimaryPercentage of Participants With Objective Response (OR)

Percentage of participants with objective response based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed response are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are those with disappearance of all target lesions. PR are those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions.

Time frame:
Baseline until disease progression or discontinuation from the study due to any cause, assessed every 6 weeks during chemotherapy phase and every 8 weeks during single agent phase up to final study visit (Week 78)
Reported as:
Number · Percentage of participants
Percentage of Participants With Objective Response (OR)
Percentage of participantsAxitinib + Cisplatin + Gemcitabine
Percentage of Participants With Objective Response (OR)39.5 (24.0 to 56.6)
SecondaryOverall Survival (OS)

Time in months from the start of study treatment to date of death due to any cause. OS was calculated as (the death date minus the date of first dose of study medication plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).

Time frame:
Baseline until death or assessed every 2 months (up to 28 days after the last dose)
Reported as:
Median · Months
Overall Survival (OS)
MonthsAxitinib + Cisplatin + Gemcitabine
Overall Survival (OS)14.2 (11.8 to 23.1)
SecondaryProgression Free Survival (PFS)

Time in months from start of study treatment to the first documentation of objective tumor progression or to death due to any cause. PFS calculated as (Months) = (first event date minus first dose date plus 1) divided by 30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").

Time frame:
Baseline, assessed every 2 months (up to 28 days after the last dose)
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsAxitinib + Cisplatin + Gemcitabine
Progression Free Survival (PFS)6.2 (4.5 to 9.3)
SecondaryDuration of Response (DR)

Time in months from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response.

Time frame:
Baseline until disease progression or discontinuation from the study due to any cause, assessed every 6 weeks during chemotherapy phase and every 8 weeks during single agent phase up to final study visit (Week 78)
Reported as:
Median · Months
Duration of Response (DR)
MonthsAxitinib + Cisplatin + Gemcitabine
Duration of Response (DR)5.78 (4.7 to 7.2)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Axitinib + Cisplatin + Gemcitabine—15/38 (39.5%)34/38 (89.5%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventAxitinib + Cisplatin + Gemcitabine
AnaemiaBlood and lymphatic system disorders2/38
Disease progressionGeneral disorders2/38
PneumoniaInfections and infestations2/38
DehydrationMetabolism and nutrition disorders2/38
NeutropeniaBlood and lymphatic system disorders1/38
HaematemesisGastrointestinal disorders1/38
FatigueGeneral disorders1/38
Multi-organ failureGeneral disorders1/38
Lung abscessInfections and infestations1/38
Femoral neck fractureInjury, poisoning and procedural complications1/38
Most frequent other events
Showing 10 of 28
Most frequent other events
EventAxitinib + Cisplatin + Gemcitabine
NauseaGastrointestinal disorders16/38
AnaemiaBlood and lymphatic system disorders11/38
VomitingGastrointestinal disorders11/38
HypertensionVascular disorders10/38
NeutropeniaBlood and lymphatic system disorders9/38
Weight decreasedInvestigations9/38
Decreased appetiteMetabolism and nutrition disorders8/38
AstheniaGeneral disorders6/38
FatigueGeneral disorders6/38
LeukopeniaBlood and lymphatic system disorders5/38

Baseline characteristics

Age Continuous
Age Continuous(Years)Axitinib + Cisplatin + Gemcitabine
Mean60.5 ± 7.1
Sex: Female, Male
Sex: Female, Male(Participants)Axitinib + Cisplatin + Gemcitabine
Female4
Male34
08

Study locations

10 sites
  • Pfizer Investigational Site
    Torun, 87-100, Poland
  • Pfizer Investigational Site
    Wodzislaw Sl., 44-300, Poland
  • Pfizer Investigational Site
    Cluj-Napoca, Cluj 400015, Romania
  • Pfizer Investigational Site
    Bucuresti, 022328, Romania
  • Pfizer Investigational Site
    Oradea, 410032, Romania
  • Pfizer Investigational Site
    Parktown, 2193, South Africa
  • Pfizer Investigational Site
    Dnipropetrovsk, 49102, Ukraine
  • Pfizer Investigational Site
    Donetsk, 83092, Ukraine
  • Pfizer Investigational Site
    Kyiv, 04107, Ukraine
  • Pfizer Investigational Site
    Lviv, 79031, Ukraine
09

References and documents

Publications

  • Bondarenko IM, Ingrosso A, Bycott P, Kim S, Cebotaru CL. Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non-small-cell lung cancer. BMC Cancer. 2015 May 1;15:339. doi: 10.1186/s12885-015-1350-6. PubMed 25929582 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2013, 1 year 2 months after primary completion. A results delay was requested in Dec 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2008
First posted
Aug 15, 2008
Start
Dec 2008
Primary completionActual
Nov 2011
CompletionActual
Nov 2011
Results delay requested
Dec 16, 2011
Results first posted
Jan 3, 2013
Last update
Jan 3, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00735904
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 15, 2008
Start date
Dec 2008
Primary completion
Nov 2011
Completion
Nov 2011
Results posted
Jan 3, 2013
Last update
Jan 3, 2013

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axitinib

Start the discussion